EuroBiotech—More articles of note


> ASIT Biotech outlined plans to raise cash for its phase 3 grass pollen induced rhinoconjunctivitis trial. The Belgian biotech plans to issue 3 million new shares. Statement

> Horama raised €19 million ($22 million). The round gives the Christine Placet-helmed gene therapy specialist the means to move its retinitis pigmentosa candidate into the clinic. Release (PDF)

> Redx escaped from administration. The British biotech is now working to get its lead cancer drug into the clinic next year. Statement (PDF) 


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Verona Pharma pulled forward the anticipated readout of top-line data from its phase 2b COPD trial. Management now expects to have date by the middle of next year, as opposed to the second half, because enrollment is proceeding faster than forecast. Release

> Erytech provided more details about its Nasdaq IPO. The French biotech is looking to raise about $125 million by offloading shares for $23 to $24 a piece. Release

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.